More recently, a randomized, placebo-controlled phase IIa trial was conducted in patients with amyotrophic lateral sclerosis (ALS) to evaluate the therapeutic effect of three 5-day cycles of low-dose IL-2 therapy (69). Here, IL2 is linked to amyotrophic lateral sclerosis.